Duke University Medical Center
Durham, North Carolina, 27710, United States
NCT Number: NCT00991185
The purpose of this study is to learn more about antimicrobials, especially drug levels in the CSF that would normally be used in young children as part of standard care. These drugs are approved by the Food and Drug Administration (FDA) for treating infections. They are used extensively in children in the United States, but they have not been extensively studied in children or babies. The investigators do not have very much information on how children and babies handle these drugs; that is, how long it takes for the drugs to be removed from the blood circulation and to pass out of the body and how much goes into the central nervous system. The investigators also do not have good information to guide how often the investigators should give the drugs to children and babies to get the maximum effect on infections with the minimum amount of drug. Thus, the investigators will collect more information about how these drugs should be used in children and babies by doing this drug levels research study.
Looking for future studies?
Notify MeUp to 18 year
All sexes
Observational
Durham, North Carolina, 27710, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: within 1 week of drug administration
CSF:serum ration of vancomycin
Duke University
Other
CSF Pharmacokinetics of Antimicrobials in Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02505386
Infections
Bordeaux, France
View Trial DetailsNCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT02231879
Agammaglobulinemia, Agranulocytosis
Bethesda, Maryland, United States
View Trial DetailsNCT05180110
Infections, Inflammation
Edinburgh, United Kingdom
View Trial Details